Notably, while IL-6 blockade promoted anti-tumor immunity in combination with anti-CTLA4, it ameliorated pathology driven by autoreactive Th17 responses,39 suggesting that IL-6/IL6R blockade may have the added benefit of attenuating immune-related adverse events. The gene discussed is CTLA4; the disease is neoplasm.